Bradykinin B2 receptor - (CHAPTER-1)

September 3, 2026: Pharvaris (NASDAQ: PHVS) summarized Bradykinin Symposium 2026 presentations on oral deucrictibant for hereditary angioedema (HAE) and bradykinin-mediated angioedema.

On-demand HAE/RAPIDe-3 (Phase 3, NCT06343779): regional subgroup data for deucrictibant immediate-release (IR) capsule were consistent across North America and Europe/Rest of World, with shorter median time to symptom relief (1.20 and 1.28 hours), attack severity reduction (2.43 and 2.53 hours), and complete resolution (11.61 and 12.04 hours) versus placebo; no serious treatment-related AEs were reported. Additional RAPIDe-3 analyses validated a PGI-C-based End of Progression (EoP) endpoint and showed significantly earlier EoP with deucrictibant versus placebo (median 17.5 minutes vs 228.7 minutes; 92.8% vs 60.9% reached EoP within 12 hours).

Long-term prophylaxis/CHAPTER-1 OLE (Phase 2, NCT05047185): mean treatment duration was 22.2 months, with up to 33.8 months total exposure; no serious treatment-related AEs or discontinuations due to TEAEs. Mean attack rate fell from 2.18/month at baseline to 0.12/month during OLE; moderate-to-severe attacks and conventionally treated attacks were each 0.06/month. AE-QoL total score improved by 26.9 points at week 86.

Other presentations covered modeled safety margins for combined XR 40 mg plus IR 20 mg use, an integrated cardiovascular safety analysis showing no QT prolongation or CV safety signals, and preclinical/in silico/proteomic work supporting pharmacology and dose prediction. The release also says deucrictibant is in ongoing late-stage trials and references NDA and MAA filings for on-demand acute HAE treatment.